Can We Select Which Patients With Small Breast Cancers Should Receive Adjuvant Chemotherapy?
نویسندگان
چکیده
منابع مشابه
Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it?
BACKGROUND Twenty percent of all newly diagnosed patients with small-cell lung cancer (SCLC) are >75 years. Elderly patients may show more toxicity due to co-morbidity. We evaluated motives for adherence to treatment guidelines, completion of treatment and toxicity. PATIENTS AND METHODS Population-based data from patients aged ≥75 years and diagnosed with SCLC in 1997-2004 in The Netherlands ...
متن کاملShould patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements. Its incidence is approximately 30 per million persons. The majority of patients with soft tissue sarcoma present with potentially life-threatening disease, and complete resection to obtain specimen margins free of tumor and radiation offer the best chance for loc...
متن کاملAdjuvant chemotherapy in luminal breast cancers.
Luminal breast cancers are traditionally considered to comprise of tumors expressing estrogen receptor (ER) and represent the majority of breast cancers. These tumors are characterized by significant heterogeneity in phenotype, molecular signature, relapse patterns and therapeutic response to endocrine and chemotherapy. Whilst adjuvant endocrine therapy is standard of care in patients with tumo...
متن کاملCombination warfarin-ASA therapy: which patients should receive it, which patients should not, and why?
Combination warfarin-ASA therapy is currently used in approximately 800,000 patients in North America as long-term treatment for the primary and secondary prevention of atherothrombotic and thromboembolic diseases. Despite a potentially complementary action of anticoagulant and antiplatelet drugs, the use of combination warfarin-ASA therapy is not based on compelling evidence of a net therapeut...
متن کاملCan We Cure Breast Cancer with Adjuvant Trastuzumab?
The news of the results from 3 recent trials of adjuvant trastuzumab treatment in early breast cancer, showing a large reduction in cancer recurrence in women with HER2-positive (HER2+) disease, is a major success for the concept of targeted therapy using biological agents. Because 20% to 30% of all newly diagnosed women have HER2+ breast cancer, making trastuzumab available to all those who st...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Surgery
سال: 2002
ISSN: 0003-4932
DOI: 10.1097/00000658-200206000-00014